Biologics drug discovery represents a revolutionary paradigm in pharmaceutical research and development, leveraging the inherent complexities of biological systems to create targeted therapeutic interventions. Unlike traditional small-molecule drugs, biologics are large, complex molecules typically derived from living organisms, such as proteins, antibodies, or nucleic acids. This approach allows for a more precise and tailored response to diseases, particularly in the realm of chronic conditions and autoimmune disorders. The process of biologics drug discovery involves unraveling the intricate biology of the targeted disease, identifying key biomolecules or pathways, and designing therapeutic agents that can modulate these targets. This nuanced understanding of the biological intricacies enables the development of therapies that exhibit higher specificity, efficacy, and often fewer side effects compared to conventional drugs.

  • The report highlights the transformative impact of biologic therapies on individuals suffering from chronic inflammatory diseases, showcasing how these treatments have not only reduced dependency on health and welfare systems but also improved patients’ physical function, enabling them to live more independently.
  • The report delves into various factors influencing the industry, including recent trends, technological advancements, and regulatory aspects. It outlines the market’s segmentation based on product, method, manufacture, and geographical regions.
  • The report strategically segments the global biologics drug discovery market based on the phase of discovery, manufacturing type, and product type.

Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent companies in this market are:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca, Plc
  • Bayer AG
  • Bicon Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lily and Company
  • F.Hoffmann-La Roche AG
  • GenScript
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Plc
  • Johnson and Johnson
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries, Ltd.

Key Questions Answered:

  • What are the major market drivers, challenges, and opportunities in the global biologics drug discovery market and their case studies?
  • How the biologics drug discovery market evolve and what did is its scope in the future?
  • What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2023 and 2033?
  • How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2033?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period between 2023 and 2033?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What will be the growth rate of the outsourced manufacturing segment during the forecast period?

This report will be delivered in 2-3 working days.